Arvinas Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
14analysts covering
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents, and Marketable Securities Quarterly614.9MTarget: Sufficient to fund planned operating expenses and capital expenditure requirements into the second half of 2028
Quarterly Revenue Quarterly15.6MTarget: 122400000 (Full Year 2026 Consensus)
Quarterly Diluted EPS Quarterly-0.9Target: Narrowing of losses through disciplined expense management
Watch Items
- VERITAC-2 Phase 3 trial interim data readout for vepdegestrant (ARV-471)Trigger: Interim efficacy and safety data releaseAction: Evaluate clinical profile against standard of care and assess commercial potential under the Pfizer collaboration
- Rigel Pharmaceuticals transition and commercialization of VEPPANUTrigger: Successful completion of select development and manufacturing transition activitiesAction: Monitor receipt of the $15.0 million transition payment and subsequent milestone/royalty distributions
- ARV-102 (LRRK2) Phase 1b trial initiation in Progressive Supranuclear Palsy (PSP)Trigger: Regulatory feedback and trial initiation in 2H 2026Action: Track regulatory clearance and patient enrollment milestones
- ARV-806 (KRAS G12D) out-licensing partner searchTrigger: Completion of Phase 1 dose-escalation trial and execution of an out-licensing agreementAction: Assess deal terms, upfront payments, and future milestone structures to validate the platform's out-licensing strategy
Research as of 19 Jun 2026